Pharmaceutical companies have sued to block a new California law that would require them to give advance notice before big price increases. A pharma trade group said in its lawsuit that California's law illegally tries to dictate national health policy.
Blue Cross and Blue Shield of Michigan will begin a new policy on Feb. 1 that limits opioid prescriptions to members to 30 days and in some cases five days.
The once-a-week shot for people with Type 2 diabetes reduces blood sugar levels and can also reduce appetite.
The monthly injection has the potential to reduce dangerous relapses that occur when patients stop taking the currently available daily medication. But that benefit has not yet been shown in studies and the new drug comes with a hefty price: $1,580 per monthly dose.
Access to affordable medicine is an unmet public health imperative, according to a new report that recommended government drug price negotiation, competition reform and financial transparency to alleviate the issue.
In his initial confirmation testimony, former pharma executive and HHS secretary nominee Alex Azar said he would stop drug manufacturers from gaming the system and blocking generic competitors from the market.
The FDA's new guidance aims to make it easier for generic firms to plan how they can copy complex drugs like epinephrine auto-injectors, which should ultimately lower pharmaceutical prices.
Pharmaceutical company founder John Kapoor, accused of leading a conspiracy to bribe doctors to prescribe a powerful opioid pain medication for people who didn't need it, has pleaded not guilty.
U.S. regulators approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.
Healthcare provider and pharmaceutical industry experts met in Franklin, Tenn., to discuss how they can partner to speed up the process of developing new drug treatments and lower the cost of life-saving therapies.
A group of pharmacies, PBMs and health plans pledged to support the federal government and states in clamping down on behaviors that have allowed opioid abuse to swell into a national epidemic, including recommendations to enforce seven-day prescriptions and e-prescribing.
Kaiser Health News, with assistance from researchers at the Mayo Clinic, analyzed available billing data from Medicare and private insurance billing nationwide, and found that spending on urine screens and related genetic tests quadrupled from 2011 to 2014 to an estimated $8.5 billion a year.